• Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)
    • Services
      • Equity Reports (Analyst-Ready)
      • Visibility Upgrades (Quartely + As needed)
      • Investor Mapping
    • Press
    • Ask AI
    • Contact
    • English
      • Deutsch (German)
      • 日本語 (Japanese)
  • info@vasro.de
  • +49 (0)69 90 28 39 81
  • Call us Mon - Fri: 8:30 AM - 6:00 PM
VASRO GmbH
VASRO GmbH
  • Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)

Press

VASRO GmbH > Press
VASRO GmbH

Vaccine makers double down on investments despite global challenges

  • April 25, 2025
  • Pharma & Biotech
Vaccine makers are boosting investments in innovation and global distribution, tackling challenges like funding cuts, regulatory scrutiny, and vaccine inequity.
Continue Reading
VASRO GmbH

2025 Market Insights: Emerging Trends in Energy and IT Industries

  • April 24, 2025
  • Energy, Tech
2025 Market Insights: Emerging trends in energy and IT include renewable energy growth, AI integration, hydrogen advancements, and decentralized systems.
Continue Reading
VASRO GmbH

Understanding Shifts in Pharma, Biotech & Tech: A 2025 Market Intelligence Brief

  • April 23, 2025
  • Pharma & Biotech
Explore how pharma, biotech, and tech are evolving by 2025 with AI, biologics, and sustainability driving growth while addressing rising costs and challenges.
Continue Reading
VASRO GmbH

How to Spot Undervalued Biotech Stocks

  • April 22, 2025
  • Pharma & Biotech
Learn how to spot undervalued biotech stocks by analyzing pipelines, market potential, and financial health to uncover high-growth investment opportunities.
Continue Reading
VASRO GmbH

Why Independent Equity Research Houses Are Key to Informed Decisions

  • April 21, 2025
  • Unkategorisiert
Independent equity research offers unbiased insights, free from conflicts of interest, empowering investors with clarity and confidence for smarter decisions.
Continue Reading
VASRO GmbH

Energy Costs in 2025: A Challenge for European Industries

  • April 18, 2025
  • Energy
Rising energy costs in 2025 challenge European industries, threatening competitiveness. Explore strategies to stabilize prices and ensure industrial resilience.
Continue Reading
VASRO GmbH

Top 10 Stocks to Watch After Q1 Earnings Reports in 2025

  • April 17, 2025
  • Unkategorisiert
Discover the top 10 post-earnings season stock picks for Q2 2025, featuring insights from Q1 earnings reports and key sectoral trends driving growth.
Continue Reading
VASRO GmbH

The Role of Sector-Specific Forecasting Models in Modern Investment Strategies

  • April 16, 2025
  • Unkategorisiert
Sector-specific forecasting models enhance investment strategies by analyzing industry-specific trends, improving accuracy, and optimizing portfolio decisions.
Continue Reading
VASRO GmbH

How Market Intelligence Drives Success in Tech Sectors​

  • April 15, 2025
  • Tech
Market intelligence empowers tech companies to analyze trends, optimize strategies, and drive growth by leveraging actionable insights for competitive success.
Continue Reading
VASRO GmbH

Navigating Market Volatility: Strategies Backed by Equity Research

  • April 14, 2025
  • Energy, Commodity, Real Estate, Pharma & Biotech, Tech
Navigate market volatility with strategies like diversification, dollar-cost averaging, and equity research to minimize risks and seize growth opportunities.
Continue Reading

Posts pagination

Previous 1 … 21 22 23 … 37 Next

Search

Categories

  • Energy
  • Equity Analysis reports
  • Equity Research Coverage
  • Market Intelligence
  • Pharma & Biotech
  • Tech
  • Unkategorisiert

Recent Posts

Sirnaomics Ltd.: The RNAimmune Money Is In, and the FDA Has Answered in Writing on STP705 October 12, 2026
Ainos, Inc.: A Partner Pays for VELDONA, and Ainos Keeps the Platform September 29, 2026
Ainos Inc: A Front-End Customer Starts Ordering, and the Dataset Passes a Billion September 16, 2026
Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace September 11, 2026
Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33 September 7, 2026
VASRO GmbH
VASRO GmbH specializes in equity analysis, market intelligence, and investment strategy for the pharmaceutical, biotechnology, and IT sectors. We deliver tailored insights to drive informed investment decisions and achieve exceptional results.

Discover More

Contact Info

  • Am Hauptbahnhof 16, 60329 Frankfurt am Main, Germany
  • +49 (0)69 90 28 39 81
  • info@vasro.de
  • 8:30 AM - 6:00 PM

Navigation

  • Imprint
  • Privacy Policy
  • Change privacy settings
  • Application
  • About
  • FAQ

©copyright 2025 VASRO GmbH.